In the future, it is expected that the treatment strategies for gastritis and GC will be optimized by precisely regulating the IL-6 signaling pathway, combined with immune checkpoint inhibitors or other treatments, and providing patients with more effective clinical interventions. Here, IL6 is linked to gastritis.